Recombinant Proteins
Product List
LRG1 Canine
Leucine-Rich Alpha-2-Glycoprotein 1 Canine
LRG1 Human
Leucine-Rich Alpha-2-Glycoprotein 1 Human Recombinant
LRG1 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
LRG1 Protein
Leucine-Rich Alpha-2-Glycoprotein 1 Human
LRG1 Human, Sf9
Leucine-Rich Alpha-2-Glycoprotein 1 Human Recombinant, Sf9
LRG1 produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 321 amino acids (36-347a.a.) and having a molecular mass of 35.4kDa. LRG1 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Introduction
Leucine-rich alpha-2-glycoprotein 1 (LRG1) is a secreted glycoprotein that belongs to the family of leucine-rich repeat (LRR) proteins. It was first discovered in human serum in 1977 . The LRR motifs are evolutionarily conserved and have been found in plants, animals, bacteria, and fungi . LRG1 is encoded by the LRG1 gene located on chromosome 19 in humans .
Key Biological Properties: LRG1 is a secreted glycoprotein involved in various biological processes, including protein-protein interactions, signal transduction, and cell adhesion .
Expression Patterns: LRG1 is constitutively expressed by hepatocytes and neutrophils . It is also expressed during granulocyte differentiation .
Tissue Distribution: LRG1 is found in various tissues, including the liver, blood, bone marrow, and adipose tissues . It is also present in the extracellular space and specific granule lumen .
Primary Biological Functions: LRG1 plays a crucial role in angiogenesis, the process of new blood vessel formation . It promotes neovascularization by modulating the transforming growth factor-beta (TGF-β) signaling pathway .
Role in Immune Responses and Pathogen Recognition: LRG1 is involved in innate immunity and the preservation of tissue integrity . It is induced in response to various inflammatory stimuli and contributes to disease pathogenesis .
Mechanisms with Other Molecules and Cells: LRG1 interacts with the accessory receptor endoglin and promotes signaling via the ALK1-Smad1/5/8 pathway . It also modulates the TGF-β signaling pathway in a context-dependent manner .
Binding Partners and Downstream Signaling Cascades: LRG1 binds to transforming growth factor-beta receptor and other molecules involved in endothelial cell proliferation and angiogenesis . It affects various cell types, including epithelial, immune, mesenchymal, and cancer cells .
Regulatory Mechanisms Controlling Expression and Activity: LRG1 expression is regulated by various non-coding RNAs, including lncRNA TUG1, which facilitates LRG1 transcription . MicroRNAs such as miR-335, miR-494, miR-497, miR-150-5p, and miR-24-3p promote the degradation of LRG1 mRNA .
Transcriptional Regulation and Post-Translational Modifications: The transcriptional regulation of LRG1 involves various signaling pathways, including the TGF-β pathway . Post-translational modifications of LRG1 are not well-documented and require further research.
Biomedical Research: LRG1 is a potential biomarker for the diagnosis, prognosis, and monitoring of multiple conditions, including cancer, diabetes, cardiovascular disease, and inflammatory disorders .
Diagnostic Tools: Elevated levels of LRG1 in acute appendicitis and various cancers suggest its use as a diagnostic aid .
Therapeutic Strategies: LRG1 is a potential therapeutic target for diseases characterized by aberrant neovascularization . Inhibition of LRG1 has been shown to normalize tumor vasculature and improve the efficacy of cytotoxic and immune therapies .
Role Throughout the Life Cycle: LRG1 is involved in various stages of the life cycle, from development to aging and disease . It plays a role in tissue integrity and immune responses, contributing to the preservation of homeostasis . In pathological conditions, LRG1 expression is upregulated, leading to disease progression .
